FDA Escalates Recall of Compounded GLP-1 Vials from Apothecary Pharma Over Sterility Risks

Key points

• Apothecary Pharma initiated a voluntary recall on Sept. 24, 2026, which the FDA updated and classified as Class II on Oct. 8, 2026.
• The recall covers 22 vials of compounded tirzepatide (18 mg/mL) and one vial of NAD+ injection (200 mg/mL) distributed nationwide.
• Affected tirzepatide lots range from AP-202622 to AP-202644, with beyond-use dates between Oct. 7 and Nov. 26, 2026.
• The FDA issued a warning letter to Apothecary Pharma in Dec. 2025 citing serious deficiencies in sterile manufacturing practices, though it has not directly linked these findings to the current recall.
• No illnesses or injuries have been reported in connection with the recalled products, but patients should monitor for signs of infection such as fever or swelling.

Background

This recall occurs amid heightened scrutiny of compounding pharmacies following the removal of tirzepatide and semaglutide from the FDA drug shortage list in late 2024 and early 2025. Although the FDA previously allowed compounding to fill gaps during shortages, many pharmacies continued production, leading to increased regulatory warnings and legal challenges from major pharmaceutical companies. Recent archive coverage notes that the FDA has received over 730 adverse event reports for compounded tirzepatide, though serious harm remains unlikely in most cases.

How outlets are covering it

LiveNOW from FOX and USA Today both confirm the core facts of the recall, including the Class II classification and the specific lot numbers. However, they emphasize different aspects of the story. LiveNOW from FOX focuses on the immediate consumer advice, urging patients to stop using affected products and seek medical attention if symptoms like fever or swelling occur. USA Today provides broader context, highlighting that these are compounded, non-FDA-approved versions of GLP-1 drugs and noting that Apothecary Pharma and the FDA did not respond to requests for comment. USA Today also draws parallels to past sterility issues, such as the 2012 fungal meningitis outbreak, to underscore the risks associated with compounding pharmacies.

Why it matters

This recall highlights ongoing safety concerns regarding compounded medications, particularly as the market for GLP-1 drugs expands. While the FDA classifies the risk as low for serious harm, the recall serves as a reminder for patients to verify the source and lot numbers of their injectable medications, especially those obtained through telehealth platforms or compounding pharmacies.

What to watch

The recall remains ongoing. Consumers are advised to check their vial lot numbers against the FDA list and contact their prescribers for guidance on disposal or replacement. The FDA continues to monitor the situation, and Apothecary Pharma is expected to continue notifying recipients of the recall.